| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/31/2026 | ±2.1% | -11.9% | under-priced |
| 05/06/2026 | ±2.2% | -2.5% | under-priced |
| 11/05/2025 | ±2.3% | +1.9% | over-priced |
| 08/07/2025 | ±1.5% | -0.2% | over-priced |
| 05/08/2025 | ±1.7% | +7.0% | under-priced |
| 11/07/2024 | ±2.3% | -5.0% | under-priced |
| 08/01/2024 | ±2.2% | -5.5% | under-priced |
| 05/02/2024 | ±1.8% | +5.7% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $1.73 | $6.4B | $1.2B |
| Q1 FY2026 | $1.07 | $4.9B | $723M |
| Q4 FY2025 | $-0.81 | $3.9B | $-549M |
| Q3 FY2025 | $-0.47 | $2.6B | $-318M |
Corteva, Inc. Common Stock (CTVA) reports in 72 days, with the next report estimated for 11/20/2026. Across the last 8 reports, options priced an average ±2.0% earnings move while the stock actually moved 5.0% on average — the market has tended to under-price CTVA's earnings risk. Fundamentals into the print: EPS down 9.9% year-over-year, revenue down 1.2%. QuantLogix's live 5-factor engine currently reads CTVA as a strong buy at 72/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →